Open Menu
Topic: Analytical services

Insight & Resources

Whitepaper

Assessing End-To-End Drug Development Partnerships

As drug development becomes increasingly expensive and complex, pharma companies are relying on the services of contract development and manufacturing organizations (CDMOs) to aid them in the creation and commercialization of their products. Exemplifying this, 80% of manufacturing by small biotech and pharma companies was outsourced in 2017. This practice allows firms to reserve precious resource for business growth activities, while CDMO partners with extensive experience and expertise can focus on the development and production of their pipelines.